Skip to Main Content

Press Releases

OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies

OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas

OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19

October 29, 2025

OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications

A PHASE 1/2A, MULTICENTER, FIRST-IN-HUMAN, OPEN-LABEL CLINICAL TRIAL EVALUATING MDX2001, A TETRASPECIFIC T CELL ENGAGER-EXPANDER IN PATIENTS WITH ADVANCED SOLID TUMOR (NCT06239194)

Follow us on LINKEDIN and TWITTER for the latest news.

Have a Question?

Email media@modextx.com

Learn more about our vision and the team behind it